Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study.

Medicina (Kaunas, Lithuania)

Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.

Medicina (Kaunas, Lithuania)

GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework.

Journal of clinical medicine

From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD.

International journal of molecular sciences

BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence.

International journal of molecular sciences

GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.

International journal of molecular sciences

Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.

International journal of molecular sciences

GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification.

International journal of molecular sciences

The compounded GLP-1 crackdown continues. Twenty state AGs sent a letter last week to Sec. Rubio claiming Chinese-sourced APIs used in compounded semaglutide, tirzepatide, and retatrutide are a supply-chain vulnerability. The AGs say that the FDA Green List for allowed imports

Kilo verme → Semaglutide, Tirzepatide, Retatrutide Libido → PT-141, Kisspeptin Kas-tendon → BPC-157, TB-500, Cilt-saç → GHK-Cu, AHK-Cu Bağırsak → BPC-157, KPV Enerji-metabolizma → MOTS-C Büyüme hormonu → CJC-1295, Ipamorelin Beyin → Semax, Selank, Dihexa Uyku → DSIP https://t.co/h9q8I8JBUr

GLP-1 Receptor Agonists & Pregnancy — What Does Human Evidence Really Say? CME INDIA CLINICAL PEARLS Singh R, Singh A, Singh AK. Human pregnancy outcomes after early glucagon-like peptide-1 receptor agonist exposure: 1. Accidental early exposure ≠ proven teratogenicity. The https://t.co/ii5AFBbv4h

A new obesity drug war has begun — in a market too large for a single winner. Lilly pushes efficacy. Novo backs amylin. Viking goes oral + injectable. Corbus bets outside incretins. Weight loss alone will not decide it. $LLY $NVO $VKTX $CRBP https://t.co/kjxtF3pOd9

RT @dogalyasalar: Kilo verme → Semaglutide, Tirzepatide, Retatrutide Libido → PT-141, Kisspeptin Kas-tendon → BPC-157, TB-500, Cilt-saç → G…

RT @dogalyasalar: Kilo verme → Semaglutide, Tirzepatide, Retatrutide Libido → PT-141, Kisspeptin Kas-tendon → BPC-157, TB-500, Cilt-saç → G…

RT @dogalyasalar: Kilo verme → Semaglutide, Tirzepatide, Retatrutide Libido → PT-141, Kisspeptin Kas-tendon → BPC-157, TB-500, Cilt-saç → G…

If you've been interested in trying peptides but haven't yet tried them yet because 1) you don't know where to start, 2) don't want to spend a fortune with your local wellness clinic (their markups are insane), but 3) you want guidance from an MD and the assurance that you're